Micro-cap clinical-stage biotechnology equities like BioRestorative Therapies typically experience sharp downward price drops due to dilution from secondary public offerings, trial delays, broader market risk aversion toward speculative health sectors, or underwhelming clinical data releases. These factors can trigger rapid sell-offs among retail and institutional holders alike.